Biosimilar development is the medium-term democratization opportunity Biocon Biologics, Samsung Bioepis, and other biosimilar developers are advancing semaglutide biosimilar programs that, upon patent expiry, could reduce drug costs by 70-85% and dramatically expand patient access in both developed markets with coverage barriers and developing markets with affordability constraints
A focused fat-loss adjunct that pairs well with GLP-1 protocols
If youre already diagnosed with either, its also the main way doctors determine how well your treatment is managing your condition.10 Out of the 96 million American adults with prediabetes, over 80% dont know they have it.11 Similarly, 20% of the 37 million adults with diabetes are unaware they have the condition
Sleep quality was assessed by dividing the participants into two groups: sufficient sleep quality and poor sleep quality
Mild discomfort during activity that resolves within an hour afterward is generally acceptable
This might not sound like a lot, but it easily clears most published thresholds for clinically meaningful improvement, especially in a population starting with high baseline pain.1 Treatment with semaglutide resulted in greater improvements than placebo across all pain-related end points, a finding that is in line with those from an observational study involving adults with knee osteoarthritis and type 2 diabetes So this trial more rigorously confirmed what had previously been one of those iffy just a correlation results, which famously does not imply causation but probably did in this case
